Novadip reports promising interim results from its first-in-human proof-of-concept trial with NVDX3, a new game changer in the bone field

At six months post-grafting surgery…

Novadip Biosciences SA Appoints Judy Ashworth, MD, as Chief Medical Officer

Mont Saint-Guibert, Belgium – December…

Novadip Biosciences SA Announces Positive Results from Phase 1/2 Clinical Trial in Patients with Severe Bone Non-Union of the Lower Limb Following Trauma

Study results demonstrate NVD-003 has…

Novadip Biosciences Raises Additional EUR 40 Million Bringing Total Company Funding to EUR 88 Million

Funding will support development of…

Novadip Biosciences announces EUR 19 million Series B financing backed by international investors

Novadip Biosciences announces EUR 19…

Novadip Biosciences reports positive data from phase I study of NVD-001 for spinal fusion

Novadip Biosciences reports positive data…

Novadip Biosciences receives IND approval from the FDA for regenerative bone product NVD-003

Novadip Biosciences receives IND approval…

Novadip Biosciences, spin-off de l’UCLouvain et les Cliniques universitaires Saint-Luc (UCLouvain) ont réalisé une première mondiale en matière de reconstruction osseuse

Première mondiale dans le domaine…

Novadip Biosciences to unveil its 3M3 Platform at BIO Digital 2020

Novadip Biosciences to unveil its…

Novadip Biosciences Reports Positive Interim Analysis of Phase I/II Bone Non-Union Study with NVD003

Novadip Biosciences Reports Positive Interim…